VRC CHKVLP059 00 VP

Drug Profile

VRC CHKVLP059 00 VP

Alternative Names: VRC-CHKVLP059-00-VP

Latest Information Update: 23 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Class Antivirals; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chikungunya virus infections

Most Recent Events

  • 30 Mar 2018 PaxVax plans a phase II trial for Chikungunya Virus Infection in April 2018 , (NCT03483961)
  • 05 Jan 2017 PaxVax in-licenses virus-like particle (VLP) vaccine technology from National Institutes of Health (NIH)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top